[Medical methods for pregnancy termination. A review of literature and its potential role in Mexico and Latin America].
In this document, we review the relevant aspects of the different medical methods of abortion. We describe the principal medical regimens currently used in North America, Europe, and a growing number of developing countries. We also describe specific treatment regimens (which usually involve a combination of two drugs), physiological methods of action, potential side effects and complications, method requirements, including follow-up visits, any existing contraindication, and acceptability of these methods among patients. Finally, we comment on the potential role of medical abortion in Mexico and throughout Latin America.
Population Council, Oficina Regional para América Latina y el Caribe, Escondida 110, Col. Villa Coyoacán, 04000 México, D. F. hespinoza@popcouncil.org.mx
Henry
H
Espinoza
Charlote
C
Ellertson
Sandy
S
García
Raffaela
R
Schiavon
Ana
A
Langer
D000020:Abortifacient Agents, Nonsteroidal / Q000494:pharmacology; D000021:Abortifacient Agents, Steroidal / Q000009:adverse effects / Q000494:pharmacology; D000028:Abortion, Induced / Q000379:methods* / Q000639:trends; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007843:Latin America; D008727:Methotrexate / Q000494:pharmacology; D008800:Mexico; D015735:Mifepristone / Q000009:adverse effects / Q000494:pharmacology; D016595:Misoprostol / Q000494:pharmacology; D009130:Muscle, Smooth / Q000187:drug effects; D010342:Patient Acceptance of Health Care; D010353:Patient Education as Topic / Q000379:methods; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology; D011372:Progestins / Q000037:antagonists & inhibitors / Q000502:physiology; D011453:Prostaglandins / Q000737:chemistry / Q000494:pharmacology; D011980:Receptors, Progesterone / Q000187:drug effects; D013762:Tetrahydrofolate Dehydrogenase / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D011372:Progestins; D011453:Prostaglandins; D011980:Receptors, Progesterone; D016595:Misoprostol; D015735:Mifepristone; D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate